These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21679968)

  • 21. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.
    Scheltema Beduin AA; Swets M; Machielsen M; Korver N;
    J Clin Psychiatry; 2012 Nov; 73(11):1395-402. PubMed ID: 23218156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients.
    Yasui-Furukori N; Saito M; Nakagami T; Furukori H; Suzuki A; Kondo T; Kaneko S
    J Psychopharmacol; 2010 Jul; 24(7):987-94. PubMed ID: 19477882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics.
    Chen JJ; Chan HY; Chen CH; Gau SS; Hwu HG
    Pharmacopsychiatry; 2012 Mar; 45(2):64-71. PubMed ID: 22086749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD; Andersen SW
    J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users.
    de Araújo AA; Ribeiro SB; Dos Santos AC; Lemos TM; Medeiros CA; Guerra GC; de Araújo Júnior RF; Serrano-Blanco A; Rubio-Valera M
    Psychiatr Q; 2016 Jun; 87(2):293-304. PubMed ID: 26220635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
    Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
    Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia.
    Casey DE; Daniel DG; Tamminga C; Kane JM; Tran-Johnson T; Wozniak P; Abi-Saab W; Baker J; Redden L; Greco N; Saltarelli M
    Neuropsychopharmacology; 2009 Apr; 34(5):1330-8. PubMed ID: 19052541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Higher motor activity in schizophrenia patients treated with olanzapine versus risperidone.
    Walther S; Horn H; Razavi N; Koschorke P; Wopfner A; Müller TJ; Strik W
    J Clin Psychopharmacol; 2010 Apr; 30(2):181-4. PubMed ID: 20520292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study.
    Strous RD; Kupchik M; Roitman S; Schwartz S; Gonen N; Mester R; Weizman A; Spivak B
    Hum Psychopharmacol; 2006 Jun; 21(4):235-43. PubMed ID: 16783815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
    McEvoy JP; Lieberman JA; Perkins DO; Hamer RM; Gu H; Lazarus A; Sweitzer D; Olexy C; Weiden P; Strakowski SD
    Am J Psychiatry; 2007 Jul; 164(7):1050-60. PubMed ID: 17606657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial.
    Takahashi H; Yoshida K; Ishigooka J; Higuchi H
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1067-72. PubMed ID: 16759777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
    Goff DC; Lamberti JS; Leon AC; Green MF; Miller AL; Patel J; Manschreck T; Freudenreich O; Johnson SA
    Neuropsychopharmacology; 2008 Feb; 33(3):465-72. PubMed ID: 17487227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia.
    Konarzewska B; Wołczyński S; Szulc A; Galińska B; Popławska R; Waszkiewicz N
    Psychoneuroendocrinology; 2009 Jan; 34(1):129-39. PubMed ID: 18838228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
    Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
    J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia.
    Kumar P B S; Pandey RS; Thirthalli J; Kumar P T S; Kumar C N
    Curr Neuropharmacol; 2017 Nov; 15(8):1073-1084. PubMed ID: 28088913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Augmentation with amisulpride for schizophrenic patients non-responsive to risperidone monotherapy.
    Toledo-Romero F; Molina JD; López-Rodríguez E; Amorin-Díaz M; Muñoz Algar MJ; Aparicio-Castro E
    Pharmacopsychiatry; 2015 Mar; 48(2):51-7. PubMed ID: 25402816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.